Back to Search
SHANNON ECCLES, DO
DO
Pediatrics Physician
NPI: 1386179083Individual
Specialties, Licenses & Credentials
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
OS018661(PA)25MB10151000(NJ)
Research & Publications (20)
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941.
PMID 19584227·Mol Cancer Ther·2009
7-preclinical
Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia.
PMID 19223463·Mol Cell Biol·2009
8-other
Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells.
PMID 19417158·Mol Cancer Ther·2009
7-preclinical
In vitro assays for endothelial cell functions related to angiogenesis: proliferation, motility, tubular differentiation, and proteolysis.
PMID 19301670·Methods Mol Biol·2009
7-preclinical
Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage.
PMID 19661439·Am J Pathol·2009
8-other
Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.
PMID 19610616·J Med Chem·2009
7-preclinical
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
PMID 19244114·Cancer Res·2009
7-preclinical
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
PMID 19197951·J Pathol·2009
8-other
The identification of novel PLC-gamma inhibitors using virtual high throughput screening.
PMID 19303309·Bioorg Med Chem·2009
8-other
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma.
PMID 19177002·Cell Cycle·2009
7-preclinical
Cross-platform Q-TOF validation of global exo-metabolomic analysis: application to human glioblastoma cells treated with the standard PI 3-Kinase inhibitor LY294002.
PMID 19101213·J Chromatogr B Analyt Technol Biomed Life Sci·2009
4-observational
With those pressures, there have been more cases of plagiarism, scientific fraud and misconduct.
PMID 19089592·Clin Exp Metastasis·2009
8-other
Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention.
PMID 19299444·Mol Endocrinol·2009
7-preclinical
A microRNA DNA methylation signature for human cancer metastasis.
PMID 18768788·Proc Natl Acad Sci U S A·2008
7-preclinical
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
PMID 18754654·J Med Chem·2008
8-other
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
PMID 18193424·Cancer Chemother Pharmacol·2008
7-preclinical
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
PMID 18413753·Cancer Res·2008
7-preclinical
CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.
PMID 18701491·Cancer Res·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 94 OLD SHORT HILLS RD
LIVINGSTON, NJ 07039 - Phone
- (973) 322-5000
Quick Facts
- NPI
- 1386179083
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile